Please ensure Javascript is enabled for purposes of website accessibility

Why Autolus Therapeutics Shares Are Plunging Today

By Keith Speights - Jan 23, 2020 at 11:44AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are reacting negatively to the biotech's public stock offering.

What happened

Shares of Autolus Therapeutics (AUTL -0.18%) are plunging today, down 18.9% as of 11:16 a.m. EST, after the biopharmaceutical company announced the pricing of a public stock offering following Wednesday's market close. Autolus is selling 7.25 million shares for $11 apiece.

So what

Secondary stock offerings typically cause a company's share price to fall. The introduction of new shares into the market dilutes the value of existing ones. It's a relatively common occurrence for biotech stocks, as companies without revenue-generating products on the market have to raise additional capital.

Test tubes with an image of DNA double helix in one test tube

Image source: Getty Images.

The good news is that the stock offerings do what they're supposed to do by bringing in more cash. In Autolus' case, the company expects its gross proceeds to total close to $80 million.

However, the timing of Autolus' stock offering raises some questions. The company had $229.4 million in cash and cash equivalents as of Sept. 30, 2019, and expects that amount is enough to fund operations into the second half of 2021.

Autolus has a couple of developments on the way this year that, if positive, could have boosted its stock price and presented a more attractive opportunity to sell shares in a secondary offering. Some investors might wonder whether Autolus doesn't expect to have good news later this year and is taking the opportunity to raise more cash now.

Now what

The main things to watch with Autolus now are those potential catalysts coming in 2020. Autolus expects to make a decision by the middle of the year on whether to advance experimental cell therapy AUT01 to a phase 2 clinical study in treating diffuse large B-cell lymphoma (DLBCL). It also should announce interim data for a phase 1 study evaluating experimental drug AUT04 in T-cell lymphoma in the second half of the year.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Autolus Therapeutics plc Stock Quote
Autolus Therapeutics plc
AUTL
$2.83 (-0.18%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.